Sanofi SA (SAN) Given a €78.00 Price Target by HSBC Holdings plc Analysts

Sanofi SA (EPA:SAN) has been given a €78.00 ($91.76) target price by HSBC Holdings plc in a note issued to investors on Friday. The firm presently has a “neutral” rating on the stock. HSBC Holdings plc’s price target indicates a potential downside of 1.29% from the company’s previous close.

Several other research analysts also recently commented on SAN. J P Morgan Chase & Co reissued a “neutral” rating on shares of Sanofi SA in a research note on Thursday, July 20th. Goldman Sachs Group, Inc. (The) set a €82.00 ($96.47) target price on Sanofi SA and gave the stock a “neutral” rating in a research note on Wednesday, July 26th. Kepler Capital Markets set a €89.00 ($104.71) target price on Sanofi SA and gave the stock a “buy” rating in a research note on Wednesday, July 26th. S&P Global set a €90.00 ($105.88) target price on Sanofi SA and gave the stock a “neutral” rating in a research note on Monday, July 31st. Finally, Berenberg Bank set a €97.00 ($114.12) target price on Sanofi SA and gave the stock a “neutral” rating in a research note on Monday, July 31st. One analyst has rated the stock with a sell rating, eleven have issued a hold rating and five have assigned a buy rating to the company. Sanofi SA currently has a consensus rating of “Hold” and an average target price of €87.24 ($102.63).

Sanofi SA (SAN) opened at €79.02 ($92.96) on Friday. Sanofi SA has a 52 week low of €70.94 ($83.46) and a 52 week high of €92.97 ($109.38).

TRADEMARK VIOLATION NOTICE: This piece was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://sportsperspectives.com/2017/11/05/sanofi-sa-san-given-a-78-00-price-target-by-hsbc-holdings-plc-analysts.html.

Sanofi SA Company Profile

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Analyst Recommendations for Sanofi SA (EPA:SAN)

Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply